Cyproheptadine for combat nightmares in post-traumatic stress disorder and dream anxiety disorder.
Military Medicine February 1, 1991 DOI: 10.1093/milmed/156.2.100 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Peer reviewed |
|---|---|
| Population | Patients with post-traumatic stress disorder experiencing combat nightmares |
| Intervention | Cyproheptadine |
| Dose | median dose of 16-24 mg orally at night |
| Topics | Anxiety Dreaming PTSD |
| Key points | The authors report that adding nighttime oral cyproheptadine at a median dose of 16-24 mg controlled combat nightmares that had persisted despite antidepressant treatment in patients with post-traumatic stress disorder. |
Abstract
Pharmacologic treatment of patients with post-traumatic stress disorder often involves antidepressant drugs. Combat nightmares often persist. The addition of cyproheptadine, in a median dose of 16-24 mg orally at night, controls the nightmares.
Citations in the library
Cited by 5
- Management of nightmares in patients with posttraumatic stress disorder: current perspectives. Nature and Science of Sleep November 26, 2018
- Management of Post-Traumatic Nightmares: a Review of Pharmacologic and Nonpharmacologic Treatments Since 2013. Current Psychiatry Reports October 11, 2018
- Position Paper for the Treatment of Nightmare Disorder in Adults: An American Academy of Sleep Medicine Position Paper. Journal of Clinical Sleep Medicine June 15, 2018
- Treatment of Post-Traumatic Stress Disorder Nightmares at a Veterans Affairs Medical Center. Journal of Clinical Medicine December 16, 2016
- Best practice guide for the treatment of nightmare disorder in adults. Journal of Clinical Sleep Medicine August 1, 2010